TY - JOUR
T1 - Lipid clinics worldwide
T2 - harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics
AU - Bork, Christian
AU - Nordestgaard, Børge G.
AU - Hedegaard, Berit Storgaard
AU - Vrablik, Michal
AU - Evans, Elsie
AU - Freiberger, Tomas
AU - Fras, Zlatko
AU - Nanchen, David
AU - Sadiq, Fouzia
AU - Ray, Kausik K.
AU - Holven, Kirsten
AU - Roeters van Lennep, Jeanine E.
AU - Laufs, Ulrich
AU - Benn, Marianne
AU - Afzal, Shoaib
AU - Liberopoulos, Evangelos
AU - Öörni, Katariina
AU - Kayikcioglu, Meral
AU - Al-Khnifsawi, Mutaz
AU - Al-Rasadi, Khalid
AU - Appiah, Lambert Tetteh
AU - Bekbossynova, Makhabbat
AU - Becker, Marianne
AU - Binder, Christoph J.
AU - Castillo, Máxima Méndez
AU - Cherska, Mariia
AU - Chlebus, Krzysztof
AU - Corral, Pablo
AU - Durst, Ronen
AU - Ezhov, Marat
AU - Gaita, Dan
AU - Galimberti, Federica
AU - Gaudet, Daniel
AU - Gamezardashvili, Tea
AU - García-Peña, Angel Alberto
AU - Groselj, Urh
AU - Harada-Shiba, Mariko
AU - Kaiser, Sergio Emanuel
AU - Latkovskis, Gustavs
AU - Maher, Vincent
AU - März, Winfried
AU - Masana, Lluís
AU - Matthias, Anne Thushara
AU - Mertens, Ann
AU - Mitchenko, Olena
AU - Nelson, Adam J.
AU - Nicholls, Stephen J.
AU - O'Brien, Richard C.
AU - Pojskic, Belma
AU - Paragh, György
AU - Petrulioniene, Zaneta
AU - Postadzhiyan, Arman
AU - Raal, Frederick J.
AU - Reda, Ashraf
AU - Reyes, Ximena
AU - Reiner, Željko
AU - Romeo, Stefano
AU - Aguilar Salinas, Carlos A.
AU - Stroes, Erik S.
AU - Symeonides, Phivos
AU - Shek, Aleksandr B.
AU - Mello e Silva, Alberto
AU - Mekonnen, Tigist
AU - Tilney, Myra
AU - Tokgozoglu, Lale
AU - Tselepis, Alexandros D.
AU - Viigimaa, Margus
AU - Vohnout, Branislav
AU - Zarate-Correa, Luz Clemencia
AU - Moulin, Philippe
N1 - Publisher Copyright:
© 2026 The Authors.
PY - 2026/7
Y1 - 2026/7
N2 - Because one in three of all individuals die from atherosclerotic cardiovascular disease (ASCVD), prevention of ASCVD is key to public health worldwide. Lipid clinics provide specialized diagnostic assessment, lifestyle management, and evidence-based lipid-lowering treatment to prevent ASCVD and acute pancreatitis in high-risk individuals. This includes individuals with familial hypercholesterolemia and/or markedly increased lipoprotein(a), statin intolerance, refractory or difficult-to-control low-density lipoprotein (LDL) cholesterol, severe hypertriglyceridaemia, and other rare or complex lipid disorders. Such specialized care not only benefits the individual patients and their families but facilitates dissemination of best practices in lipid disorder management to healthcare professionals in individual nations. Despite this, there is a lack of guidance on standards and metrics needed to establish a well-harmonized national lipid clinic network in most countries capable of offering comprehensive care. This consensus paper from the European Atherosclerosis Society Lipid Clinic Network aims to meet this unmet clinical need. We provide recommendations to enhance education and training on lipid disorders and to harmonize lipid clinics at both national and international levels. Furthermore, we provide guidance on optimal staffing structures and development of registries to improve diagnosis and management of lipid disorders. Finally, we offer recommendations to national and regional policymakers on funding of lipid clinics, with the long-term goal of reducing the overall societal burden and costs of cardiovascular and other lipid-related diseases.
AB - Because one in three of all individuals die from atherosclerotic cardiovascular disease (ASCVD), prevention of ASCVD is key to public health worldwide. Lipid clinics provide specialized diagnostic assessment, lifestyle management, and evidence-based lipid-lowering treatment to prevent ASCVD and acute pancreatitis in high-risk individuals. This includes individuals with familial hypercholesterolemia and/or markedly increased lipoprotein(a), statin intolerance, refractory or difficult-to-control low-density lipoprotein (LDL) cholesterol, severe hypertriglyceridaemia, and other rare or complex lipid disorders. Such specialized care not only benefits the individual patients and their families but facilitates dissemination of best practices in lipid disorder management to healthcare professionals in individual nations. Despite this, there is a lack of guidance on standards and metrics needed to establish a well-harmonized national lipid clinic network in most countries capable of offering comprehensive care. This consensus paper from the European Atherosclerosis Society Lipid Clinic Network aims to meet this unmet clinical need. We provide recommendations to enhance education and training on lipid disorders and to harmonize lipid clinics at both national and international levels. Furthermore, we provide guidance on optimal staffing structures and development of registries to improve diagnosis and management of lipid disorders. Finally, we offer recommendations to national and regional policymakers on funding of lipid clinics, with the long-term goal of reducing the overall societal burden and costs of cardiovascular and other lipid-related diseases.
KW - Atherosclerosis
KW - Hyperlipidaemia
KW - Hypolipidaemia
KW - Myocardial infarction
KW - Pancreatitis
KW - Peripheral artery disease
KW - Prevention
KW - Stroke
UR - https://www.scopus.com/pages/publications/105040961308
U2 - 10.1016/j.atherosclerosis.2026.120757
DO - 10.1016/j.atherosclerosis.2026.120757
M3 - Journal article
C2 - 42178198
AN - SCOPUS:105040961308
SN - 0021-9150
VL - 418
JO - Atherosclerosis
JF - Atherosclerosis
M1 - 120757
ER -